ASCO Video Pearls: Metastatic Breast Cancer

Maryam Lustberg, MD, details three posters she was a discussant on at ASCO 2023

Those 65 and up had the same efficacy along with an "acceptable" increase in toxicity

Including CDK4/6 inhibitor with endocrine therapy improved invasive disease-free survival

Megan Kruse, MD, says we need to balance the efficacy and toxicity in a real-world setting

Lasofoxifene plus abemaciclib elicited encouraging PFS with an acceptable toxicity profile

Jane Meisel, MD, discusses the implications of the TROPiCS-02 study

Trastuzumab deruxtecan shows remarkable improvement in progression-free and overall survival

William Gradishar discusses the PALOMA-3 and MONALEESA-3 trials

Sayeh Lavasani discusses the latest updates from MONALEESA-3

A promising strategy for improving responses with checkpoint inhibition

Nearly six times more likely to develop distant metastases after diagnosis than white women